Silybin was first isolated from the seed of Silybum marianum. It showed anti-tumor activity by inhibiting the growth of cancer cell lines, possibly by promoting the degradation of multiple HSP90-dependent client proteins, including HER2, RAF1, Akt, CDK2, CDK4 [224,225]. The gene discussed is HSP90AB1; the disease is cancer.